Financing the global response to the epidemic will cost $9.2 billion a year, according to one estimate
11 September 2002. Related: Conference reports, Treatment access.
Conference reports
The Global Fund: what, where, how much?
11 September 2002. Related: Conference reports, Treatment access.
Leading businesses spurn Global Fund
11 September 2002. Related: Conference reports, Treatment access.
14 Caribbean governments sign cut-price drugs agreement with six pharmaceutical companies
11 September 2002. Related: Conference reports, Treatment access.
Thailand offers low-cost transfer to African countries of technology for the local production of generic antiretrovirals
11 September 2002. Related: Conference reports, Treatment access.
Informal market plays a role in distributing antiretrovirals but exposes clients to risks
11 September 2002. Related: Conference reports, Treatment access.
Abacavir hypersensitivity reactions in patients who rechallenge after interruptions for reasons other than hypersensitivity
11 September 2002. Related: Conference reports, Side effects.
Prolonged CNS side-effects of efavirenz can be severe and lead to treatment discontinuation
11 September 2002. Related: Conference reports, Side effects.
Four drug regimen for infants
11 September 2002. Related: Conference reports, Paediatric care.
Study of MTCT programme finds resistance in women on two doses of monotherapy
11 September 2002. Related: Conference reports, Pregnancy, Drug resistance.
Emergence of resistance in children treated with ddI/d4T after treatment to reduce MTCT
11 September 2002. Related: Conference reports, Paediatric care.
Correlates of fatigue in HIV disease
11 September 2002. Related: Conference reports.
Optimum hydroxyurea dose determined
11 September 2002. Related: Conference reports.
Management of people with treatment experience and drug resistance
11 September 2002. Related: Conference reports, Antiretrovirals.
HIV-associated malignancies in the HAART era: flickers of hope and understanding
11 September 2002. Related: Conference reports, Cancer and HIV.
Lopinavir/r exhibits sustained virologic response in antiretroviral-naïve patients: 3-year data
11 September 2002. Related: Conference reports, Antiretrovirals.
Patients will have options regarding T-20 (enfuvirtide) injection sites
11 September 2002. Related: Conference reports, Antiretrovirals.
The role of tenofovir in antiretroviral-naive patients
11 September 2002. Related: Conference reports, Antiretrovirals.
Treatment interruption strategy reports from the XIV International AIDS Conference
11 September 2002. Related: Conference reports, Treatment strategies.
New data from clinical trials of antiretrovirals
11 September 2002. Related: Conference reports, Antiretrovirals.
Behind the headlines about vaccine research
11 September 2002. Related: Conference reports, Vaccines and microbicides.
9th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, Februrary 24-28 2002
11 June 2002. Related: Conference reports.
New research points the way for future treatment of women with HIV
11 June 2002. Related: Conference reports, Women's health.
3rd International Workshop on Clinical Pharmacology of HIV Therapy, Washington, 11-13 April 2002
11 June 2002. Related: Conference reports.
Three studies compare gender differences in use of antiretrovirals
11 June 2002. Related: Conference reports.
9th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, Februrary 24-28 2002
10 April 2002. Related: Conference reports.
Study results shed light on cardiovascular risks: role of antiretrovirals and metabolism of lipids and sugars
10 April 2002. Related: Conference reports, Side effects, Weight, diabetes, metabolic complications.
Switch to abacavir improves lipoatrophy
10 April 2002. Related: Conference reports, Side effects, Weight, diabetes, metabolic complications.
Potential use of niacin to reduce intra-abdominal fat
10 April 2002. Related: Conference reports, Side effects, Weight, diabetes, metabolic complications.
Further benefits shown with New-Fill for facial atrophy
10 April 2002. Related: Conference reports, Side effects, Weight, diabetes, metabolic complications.
Lipodystrophy associated with lower CD4+ T cell counts
10 April 2002. Related: Conference reports, Side effects, Weight, diabetes, metabolic complications.
Treatment interruptions
10 April 2002. Related: Conference reports.
Analysis of cells from long term non-progressors points the way to using vaccines and STIs to restore immune response to HIV
10 April 2002. Related: Conference reports.
Symposium on T cell turnover and thymic function
10 April 2002. Related: Conference reports.
New drugs: perhaps some genuine excitement this time
10 April 2002. Related: Conference reports, Antiretrovirals.
T20 and beyond: inhibition of HIV attachment and fusion at the 9th CROI
10 April 2002. Related: Conference reports, Antiretrovirals.
Pharmacogenetics predict abacavir hypersensitivity
10 April 2002. Related: Conference reports, Antiretrovirals.
Pregnancy: growing body of evidence supports treating maternal disease
10 April 2002. Related: Conference reports, Pregnancy.
Peripheral neuropathy update
10 April 2002. Related: Conference reports, Side effects.
41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 16-19 December 2001
9 January 2002. Related: Conference reports.
Low dose pegylated interferon is ineffective in treating HIV/HCV co-infected patients
9 January 2002. Related: Conference reports, Hepatitis coinfection.
Phenotypic resistance to ddI is less frequent than resistance to ZDV, 3TC and abacavir
9 January 2002. Related: Conference reports, Drug resistance.
Impact of Kaletra on amprenavir plasma concentrations in HIV treatment-experienced patients
9 January 2002. Related: Conference reports, Antiretrovirals.
Immune reconstitution more difficult with low baseline CD4+ T cell counts
9 January 2002. Related: Conference reports.
HIV-1 may revert to less pathogenic strain a few days after starting HAART
9 January 2002. Related: Conference reports, Basic science and immunology.
Change from CCR5 to CXCR4 phenotype may affect immunologic responses
9 January 2002. Related: Conference reports.
ddI EC (Videx) study confirms and clarifies dosing on an empty stomach
9 January 2002. Related: Conference reports, Antiretrovirals.
Swatch study: should we be cycling drugs?
9 January 2002. Related: Conference reports, Antiretrovirals.
New HIV drugs, resistance, pharmacogenomics
9 January 2002. Related: Conference reports, Antiretrovirals.
Antiretroviral therapy
9 January 2002. Related: Conference reports, Antiretrovirals.
Immunopathogenesis of HIV infection
9 January 2002. Related: Conference reports.
3rd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Athens, 23-26 October 2001
9 December 2001. Related: Conference reports.
Insulin resistance
9 December 2001. Related: Conference reports.
Thyroid function abnormalities
9 December 2001. Related: Conference reports.
Lipodystrophy and metabolic changes in children
9 December 2001. Related: Conference reports, Paediatric care.
Bone studies at lipodystrophy workshop
9 December 2001. Related: Conference reports.
8th European Conference on Clinical Aspects and Treatment of HIV-infection, Athens, 28-31 October 2001
2 November 2001. Related: Conference reports.
HIV drug resistance can develop under HAART at low levels of viraemia
2 November 2001. Related: Conference reports, Drug resistance.
Combinations of lopinavir/r and amprenavir in heavily treatment experienced patients
2 November 2001. Related: Conference reports, PK and drug interactions.
Further reports of benefits of polylactic acid for facial lipoatrophy
2 November 2001. Related: Conference reports, Side effects, Weight, diabetes, metabolic complications.
GigaHAART study shows benefit of treatment interruption prior to treatment with >7 drugs in highly treatment experienced patients
2 November 2001. Related: Conference reports, Drug resistance.
Tenofovir DF 907 study
2 November 2001. Related: Conference reports, Antiretrovirals.
The Max Cmin 1 trial: indinavir/ritonavir vs. saquinavir/ritonavir
2 November 2001. Related: Conference reports, Antiretrovirals.
No significant drug interactions found between tenofovir DF and indinavir, lopinavir/r, lamivudine, or efavirenz
2 November 2001. Related: Conference reports, PK and drug interactions.
Ritonavir corrects drug interaction between efavirenz and saquinavir
2 November 2001. Related: Conference reports, PK and drug interactions.